|
1
|
Olaiz N, Monti Hughes A, Pozzi ECC, Thorp S, Curotto P, Trivillin VA, Ramos PS, Palmieri MA, Marshall G, Schwint AE, Garabalino MA. Enhancement in the Therapeutic Efficacy of In Vivo BNCT Mediated by GB-10 with Electroporation in a Model of Oral Cancer. Cells 2023; 12:cells12091241. [PMID: 37174642 PMCID: PMC10177359 DOI: 10.3390/cells12091241] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2023] [Revised: 04/17/2023] [Accepted: 04/20/2023] [Indexed: 05/15/2023] Open
Abstract
Boron neutron capture therapy (BNCT) combines preferential tumor uptake of 10B compounds and neutron irradiation. Electroporation induces an increase in the permeability of the cell membrane. We previously demonstrated the optimization of boron biodistribution and microdistribution employing electroporation (EP) and decahydrodecaborate (GB-10) as the boron carrier in a hamster cheek pouch oral cancer model. The aim of the present study was to evaluate if EP could improve tumor control without enhancing the radiotoxicity of BNCT in vivo mediated by GB-10 with EP 10 min after GB-10 administration. Following cancerization, tumor-bearing hamster cheek pouches were treated with GB-10/BNCT or GB-10/BNCT + EP. Irradiations were carried out at the RA-3 Reactor. The tumor response and degree of mucositis in precancerous tissue surrounding tumors were evaluated for one month post-BNCT. The overall tumor response (partial remission (PR) + complete remission (CR)) increased significantly for protocol GB-10/BNCT + EP (92%) vs. GB-10/BNCT (48%). A statistically significant increase in the CR was observed for protocol GB-10/BNCT + EP (46%) vs. GB-10/BNCT (6%). For both protocols, the radiotoxicity (mucositis) was reversible and slight/moderate. Based on these results, we concluded that electroporation improved the therapeutic efficacy of GB-10/BNCT in vivo in the hamster cheek pouch oral cancer model without increasing the radiotoxicity.
Collapse
Affiliation(s)
- Nahuel Olaiz
- Departamento de Física, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires (UBA), Pabellón I, Ciudad Universitaria, Buenos Aires C1428EHA, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2270, Buenos Aires C1425FQD, Argentina
| | - Andrea Monti Hughes
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2270, Buenos Aires C1425FQD, Argentina
- Departamento Radiobiología, Comisión Nacional de Energía Atómica (CNEA), Centro Atómico Constituyentes (CAC), Av. General Paz 1499, San Martín, Buenos Aires B1650KNA, Argentina
| | - Emiliano C C Pozzi
- Departamento de Reactores de Investigación y Producción, Comisión Nacional de Energía Atómica (CNEA), Centro Atómico Ezeiza (CAE), Camino Real Presbítero González y Aragón 15, Buenos Aires B1802AYA, Argentina
| | - Silvia Thorp
- Sub-Gerencia Instrumentación y Control, Comisión Nacional de Energía Atómica (CNEA), Centro Atómico Ezeiza (CAE), Camino Real Presbítero González y Aragón 15, Buenos Aires B1802AYA, Argentina
| | - Paula Curotto
- Departamento de Reactores de Investigación y Producción, Comisión Nacional de Energía Atómica (CNEA), Centro Atómico Ezeiza (CAE), Camino Real Presbítero González y Aragón 15, Buenos Aires B1802AYA, Argentina
| | - Verónica A Trivillin
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2270, Buenos Aires C1425FQD, Argentina
- Departamento Radiobiología, Comisión Nacional de Energía Atómica (CNEA), Centro Atómico Constituyentes (CAC), Av. General Paz 1499, San Martín, Buenos Aires B1650KNA, Argentina
| | - Paula S Ramos
- Departamento Radiobiología, Comisión Nacional de Energía Atómica (CNEA), Centro Atómico Constituyentes (CAC), Av. General Paz 1499, San Martín, Buenos Aires B1650KNA, Argentina
| | - Mónica A Palmieri
- Departamento de Biodiversidad y Biología Experimental, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires (UBA), Pabellón II, Ciudad Universitaria, Buenos Aires C1428EHA, Argentina
| | - Guillermo Marshall
- Departamento de Física, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires (UBA), Pabellón I, Ciudad Universitaria, Buenos Aires C1428EHA, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2270, Buenos Aires C1425FQD, Argentina
| | - Amanda E Schwint
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2270, Buenos Aires C1425FQD, Argentina
- Departamento Radiobiología, Comisión Nacional de Energía Atómica (CNEA), Centro Atómico Constituyentes (CAC), Av. General Paz 1499, San Martín, Buenos Aires B1650KNA, Argentina
| | - Marcela A Garabalino
- Departamento Radiobiología, Comisión Nacional de Energía Atómica (CNEA), Centro Atómico Constituyentes (CAC), Av. General Paz 1499, San Martín, Buenos Aires B1650KNA, Argentina
| |
Collapse
|
|
2
|
Importance of radiobiological studies for the advancement of boron neutron capture therapy (BNCT). Expert Rev Mol Med 2022; 24:e14. [PMID: 35357286 DOI: 10.1017/erm.2022.7] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Boron neutron capture therapy (BNCT) is a tumour selective particle radiotherapy, based on the administration of boron carriers incorporated preferentially by tumour cells, followed by irradiation with a thermal or epithermal neutron beam. BNCT clinical results to date show therapeutic efficacy, associated with an improvement in patient quality of life and prolonged survival. Translational research in adequate experimental models is necessary to optimise BNCT for different pathologies. This review recapitulates some examples of BNCT radiobiological studies for different pathologies and clinical scenarios, strategies to optimise boron targeting, enhance BNCT therapeutic effect and minimise radiotoxicity. It also describes the radiobiological mechanisms induced by BNCT, and the importance of the detection of biomarkers to monitor and predict the therapeutic efficacy and toxicity of BNCT alone or combined with other strategies. Besides, there is a brief comment on the introduction of accelerator-based neutron sources in BNCT. These sources would expand the clinical BNCT services to more patients, and would help to make BNCT a standard treatment modality for various types of cancer. Radiobiological BNCT studies have been of utmost importance to make progress in BNCT, being essential to design novel, safe and effective clinical BNCT protocols.
Collapse
|
|
3
|
Van der Weyden L, O'Dell N, Avenant A, Pazzi P, Koeppel KN. Successful treatment of early cutaneous squamous cell carcinoma with hypofractionated radiation therapy in an African lion (Panthera leo). J S Afr Vet Assoc 2021; 92:e1-e6. [PMID: 34212735 PMCID: PMC8252176 DOI: 10.4102/jsava.v92i0.2134] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2020] [Revised: 04/07/2021] [Accepted: 04/08/2021] [Indexed: 11/09/2022] Open
Abstract
Cutaneous squamous cell carcinoma (SCC) is a slow growing but locally invasive neoplasm, most commonly caused by prolonged exposure to ultraviolet (UV) radiation. Whilst SCC accounts for 15% of skin tumours in domesticated cats, cutaneous SCC in non-domesticated felids (apart from captive snow leopards) appears to be uncommon, with only three reports in the literature to date. In this report, a captive African lion (Panthera leo) presented with two ulcerative lesions on the nasal planum. Histopathology of the lesions revealed epidermal keratinocyte dysplasia and neoplastic basal- and supra-basal epithelial cells with dyskeratosis and evidence of basement membrane breaching and dermal invasion, consistent with a diagnosis of SCC. There was also evidence of laminar fibrosis and inflammation of the subjacent dermis suggesting that the SCC most likely resulted from UV-induced neoplastic transformation of the epidermal squamous epithelium following actinic keratosis. The lion was treated with hypofractionated radiation therapy and remained in remission until his death (euthanised 17 months later because of age-related chronic renal failure). This is the first report of cutaneous SCC in a lion with evidence of actinic damage and resolution after radiation therapy.
Collapse
|
|
4
|
Schwint AE, Monti Hughes A, Garabalino MA, Santa Cruz GA, González SJ, Longhino J, Provenzano L, Oña P, Rao M, Cantarelli MDLÁ, Leiras A, Olivera MS, Trivillin VA, Alessandrini P, Brollo F, Boggio E, Costa H, Ventimiglia R, Binia S, Pozzi ECC, Nievas SI, Santa Cruz IS. Clinical Veterinary Boron Neutron Capture Therapy (BNCT) Studies in Dogs with Head and Neck Cancer: Bridging the Gap between Translational and Clinical Studies. BIOLOGY 2020; 9:biology9100327. [PMID: 33036386 PMCID: PMC7599538 DOI: 10.3390/biology9100327] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/18/2020] [Revised: 10/01/2020] [Accepted: 10/05/2020] [Indexed: 01/08/2023]
Abstract
Simple Summary Boron Neutron Capture Therapy (BNCT) is a treatment for cancer based on the selective accumulation in tumor of boron compounds, followed by external irradiation with neutrons. The interaction between boron-10 and a neutron gives rise to very energetic particles that travel only a very short distance (approximately the diameter of a cell) and are lethal for the cell. In this way, BNCT damages tumor tissue selectively while preserving normal tissue. BNCT has proved effective to treat certain tumors in clinical trials worldwide, with room for improvement. Our group has worked on animal models to improve the efficacy of BNCT, in particular for head and neck cancer. Herein we performed clinical veterinary BNCT studies in five terminal dog patients with head and neck cancer with no other therapeutic option. In all cases we observed partial tumor response, clinical benefit, and extension of estimated survival time at recruitment with excellent quality of life. Toxicity associated to the treatment was mild/moderate and reversible. These studies contribute towards preparation for clinical BNCT trials for head and neck cancer in Argentina and suggest a potential role for BNCT in veterinary medicine. Abstract Translational Boron Neutron Capture Therapy (BNCT) studies performed by our group and clinical BNCT studies worldwide have shown the therapeutic efficacy of BNCT for head and neck cancer. The present BNCT studies in veterinary patients with head and neck cancer were performed to optimize the therapeutic efficacy of BNCT, contribute towards exploring the role of BNCT in veterinary medicine, put in place technical aspects for an upcoming clinical trial of BNCT for head and neck cancer at the RA-6 Nuclear Reactor, and assess the feasibility of employing the existing B2 beam to treat large, deep-seated tumors. Five dogs with head and neck cancer with no other therapeutic option were treated with two applications of BNCT mediated by boronophenyl-alanine (BPA) separated by 3–5 weeks. Two to three portals per BNCT application were used to achieve a potentially therapeutic dose over the tumor without exceeding normal tissue tolerance. Clinical and Computed Tomography results evidenced partial tumor control in all cases, with slight-moderate mucositis, excellent life quality, and prolongation in the survival time estimated at recruitment. These exploratory studies show the potential value of BNCT in veterinary medicine and contribute towards initiating a clinical BNCT trial for head and neck cancer at the RA-6 clinical facility.
Collapse
Affiliation(s)
- Amanda E. Schwint
- National Atomic Energy Commission (CNEA), Avenida del Libertador 8250, C1429 BNP, Buenos Aires, Argentina; (A.M.H.); (M.A.G.); (G.A.S.C.); (S.J.G.); (J.L.); (L.P.); (M.S.O.); (V.A.T.); (F.B.); (E.B.); (E.C.C.P.); (S.I.N.); (I.S.S.C.)
- National Research Council (CONICET), Godoy Cruz 2290, C1425FQB, Buenos Aires, Argentina
- Correspondence: ; Tel.: +54-911-6496-7168
| | - Andrea Monti Hughes
- National Atomic Energy Commission (CNEA), Avenida del Libertador 8250, C1429 BNP, Buenos Aires, Argentina; (A.M.H.); (M.A.G.); (G.A.S.C.); (S.J.G.); (J.L.); (L.P.); (M.S.O.); (V.A.T.); (F.B.); (E.B.); (E.C.C.P.); (S.I.N.); (I.S.S.C.)
- National Research Council (CONICET), Godoy Cruz 2290, C1425FQB, Buenos Aires, Argentina
| | - Marcela A. Garabalino
- National Atomic Energy Commission (CNEA), Avenida del Libertador 8250, C1429 BNP, Buenos Aires, Argentina; (A.M.H.); (M.A.G.); (G.A.S.C.); (S.J.G.); (J.L.); (L.P.); (M.S.O.); (V.A.T.); (F.B.); (E.B.); (E.C.C.P.); (S.I.N.); (I.S.S.C.)
| | - Gustavo A. Santa Cruz
- National Atomic Energy Commission (CNEA), Avenida del Libertador 8250, C1429 BNP, Buenos Aires, Argentina; (A.M.H.); (M.A.G.); (G.A.S.C.); (S.J.G.); (J.L.); (L.P.); (M.S.O.); (V.A.T.); (F.B.); (E.B.); (E.C.C.P.); (S.I.N.); (I.S.S.C.)
| | - Sara J. González
- National Atomic Energy Commission (CNEA), Avenida del Libertador 8250, C1429 BNP, Buenos Aires, Argentina; (A.M.H.); (M.A.G.); (G.A.S.C.); (S.J.G.); (J.L.); (L.P.); (M.S.O.); (V.A.T.); (F.B.); (E.B.); (E.C.C.P.); (S.I.N.); (I.S.S.C.)
- National Research Council (CONICET), Godoy Cruz 2290, C1425FQB, Buenos Aires, Argentina
| | - Juan Longhino
- National Atomic Energy Commission (CNEA), Avenida del Libertador 8250, C1429 BNP, Buenos Aires, Argentina; (A.M.H.); (M.A.G.); (G.A.S.C.); (S.J.G.); (J.L.); (L.P.); (M.S.O.); (V.A.T.); (F.B.); (E.B.); (E.C.C.P.); (S.I.N.); (I.S.S.C.)
| | - Lucas Provenzano
- National Atomic Energy Commission (CNEA), Avenida del Libertador 8250, C1429 BNP, Buenos Aires, Argentina; (A.M.H.); (M.A.G.); (G.A.S.C.); (S.J.G.); (J.L.); (L.P.); (M.S.O.); (V.A.T.); (F.B.); (E.B.); (E.C.C.P.); (S.I.N.); (I.S.S.C.)
- National Research Council (CONICET), Godoy Cruz 2290, C1425FQB, Buenos Aires, Argentina
| | - Paulina Oña
- Fundación INTECNUS: Instituto de Tecnologías Nucleares para la Salud, Ruta Provincial 82, San Carlos de Bariloche, R8402AGP, Provincia Rio Negro, Argentina; (P.O.); (H.C.); (R.V.); (S.B.)
| | - Monica Rao
- Hospital Veterinario, Gobernador M. Ugarte 2152, Olivos, B1636BWT, Provincia Buenos Aires, Argentina;
| | | | - Andrea Leiras
- Independent Veterinarian, Huilqui 12356, San Carlos de Bariloche, 8400, Provincia Rio Negro, Argentina;
| | - María Silvina Olivera
- National Atomic Energy Commission (CNEA), Avenida del Libertador 8250, C1429 BNP, Buenos Aires, Argentina; (A.M.H.); (M.A.G.); (G.A.S.C.); (S.J.G.); (J.L.); (L.P.); (M.S.O.); (V.A.T.); (F.B.); (E.B.); (E.C.C.P.); (S.I.N.); (I.S.S.C.)
| | - Verónica A. Trivillin
- National Atomic Energy Commission (CNEA), Avenida del Libertador 8250, C1429 BNP, Buenos Aires, Argentina; (A.M.H.); (M.A.G.); (G.A.S.C.); (S.J.G.); (J.L.); (L.P.); (M.S.O.); (V.A.T.); (F.B.); (E.B.); (E.C.C.P.); (S.I.N.); (I.S.S.C.)
- National Research Council (CONICET), Godoy Cruz 2290, C1425FQB, Buenos Aires, Argentina
| | - Paula Alessandrini
- Independent Veterinarian, Lonquimay 3817, San Carlos de Bariloche, 8400, Provincia Rio Negro, Argentina;
| | - Fabricio Brollo
- National Atomic Energy Commission (CNEA), Avenida del Libertador 8250, C1429 BNP, Buenos Aires, Argentina; (A.M.H.); (M.A.G.); (G.A.S.C.); (S.J.G.); (J.L.); (L.P.); (M.S.O.); (V.A.T.); (F.B.); (E.B.); (E.C.C.P.); (S.I.N.); (I.S.S.C.)
| | - Esteban Boggio
- National Atomic Energy Commission (CNEA), Avenida del Libertador 8250, C1429 BNP, Buenos Aires, Argentina; (A.M.H.); (M.A.G.); (G.A.S.C.); (S.J.G.); (J.L.); (L.P.); (M.S.O.); (V.A.T.); (F.B.); (E.B.); (E.C.C.P.); (S.I.N.); (I.S.S.C.)
| | - Hernan Costa
- Fundación INTECNUS: Instituto de Tecnologías Nucleares para la Salud, Ruta Provincial 82, San Carlos de Bariloche, R8402AGP, Provincia Rio Negro, Argentina; (P.O.); (H.C.); (R.V.); (S.B.)
| | - Romina Ventimiglia
- Fundación INTECNUS: Instituto de Tecnologías Nucleares para la Salud, Ruta Provincial 82, San Carlos de Bariloche, R8402AGP, Provincia Rio Negro, Argentina; (P.O.); (H.C.); (R.V.); (S.B.)
| | - Sergio Binia
- Fundación INTECNUS: Instituto de Tecnologías Nucleares para la Salud, Ruta Provincial 82, San Carlos de Bariloche, R8402AGP, Provincia Rio Negro, Argentina; (P.O.); (H.C.); (R.V.); (S.B.)
| | - Emiliano C. C. Pozzi
- National Atomic Energy Commission (CNEA), Avenida del Libertador 8250, C1429 BNP, Buenos Aires, Argentina; (A.M.H.); (M.A.G.); (G.A.S.C.); (S.J.G.); (J.L.); (L.P.); (M.S.O.); (V.A.T.); (F.B.); (E.B.); (E.C.C.P.); (S.I.N.); (I.S.S.C.)
| | - Susana I. Nievas
- National Atomic Energy Commission (CNEA), Avenida del Libertador 8250, C1429 BNP, Buenos Aires, Argentina; (A.M.H.); (M.A.G.); (G.A.S.C.); (S.J.G.); (J.L.); (L.P.); (M.S.O.); (V.A.T.); (F.B.); (E.B.); (E.C.C.P.); (S.I.N.); (I.S.S.C.)
| | - Iara S. Santa Cruz
- National Atomic Energy Commission (CNEA), Avenida del Libertador 8250, C1429 BNP, Buenos Aires, Argentina; (A.M.H.); (M.A.G.); (G.A.S.C.); (S.J.G.); (J.L.); (L.P.); (M.S.O.); (V.A.T.); (F.B.); (E.B.); (E.C.C.P.); (S.I.N.); (I.S.S.C.)
| |
Collapse
|
|
5
|
Lino M, Lanore D, Lajoinie M, Jimenez A, Crouzet F, Queiroga FL. Prognostic factors for cats with squamous cell carcinoma of the nasal planum following high-dose rate brachytherapy. J Feline Med Surg 2019; 21:1157-1164. [PMID: 30667286 PMCID: PMC10814269 DOI: 10.1177/1098612x18822409] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
OBJECTIVES The aim of the study was to investigate retrospectively the prognostic impact of variables such as sex, neuter status, breed, age, number of lesions, location and size of the tumour, tumour extension beyond the nasal planum, ulceration and lymph node status, among others, in a population of cats treated with high-dose rate brachytherapy. METHODS This study reviews the outcome of 58 cats with cytologically and/or histologically confirmed squamous cell carcinoma of the nasal planum, treated at the Clinic Alliance (Bordeaux, France) with high-dose rate brachytherapy from 2010-2016. The total radiation dose delivered was 30 Gy, administered in two different schedules: five fractions of 6 Gy for a period of 4 days (Tuesday-Friday) or four fractions of 7.5 Gy for a period of 3 days (Tuesday- Thursday). Data were collected from cats' clinical records. RESULTS Complete response was achieved in 72% (n = 36) of the cats, partial response in 24% (n = 13) and 2% (n = 1) did not respond. Median progression-free survival and overall survival times were 316 and 835 days, respectively. CONCLUSIONS AND RELEVANCE Results indicated that sex (P = 0.045), extension of the tumour from the nasal planum to the upper lip (P = 0.015), tumour size (P = 0.015; P = 0.001), the existence of a previous treatment (P = 0.043) and the tumour response to high-dose rate brachytherapy (P = 0.038; P <0.001) are prognostic factors for cats with squamous cell carcinoma of the nasal planum following high-dose rate brachytherapy.
Collapse
Affiliation(s)
- Mafalda Lino
- Department of Veterinary Sciences, University of Trás-os-Montes and Alto Douro, Vila Real, Portugal
| | | | | | - Ana Jimenez
- Veterinary Clinic Alliance, Bordeaux, France
| | | | - Felisbina L Queiroga
- Department of Veterinary Sciences, University of Trás-os-Montes and Alto Douro, Vila Real, Portugal
- Center for the Study of Animal Sciences, Institute of Sciences, Technologies and Agro-environment, University of Porto, Porto, Portugal
- Center for Research and Technology of Agro-Environment and Biological Sciences, University of Trás-os-Montes and Alto Douro, Vila Real, Portugal
| |
Collapse
|
|
6
|
Garabalino MA, Olaiz N, Portu A, Saint Martin G, Thorp SI, Pozzi ECC, Curotto P, Itoiz ME, Monti Hughes A, Colombo LL, Nigg DW, Trivillin VA, Marshall G, Schwint AE. Electroporation optimizes the uptake of boron-10 by tumor for boron neutron capture therapy (BNCT) mediated by GB-10: a boron biodistribution study in the hamster cheek pouch oral cancer model. RADIATION AND ENVIRONMENTAL BIOPHYSICS 2019; 58:455-467. [PMID: 31123853 DOI: 10.1007/s00411-019-00796-z] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/22/2018] [Accepted: 05/07/2019] [Indexed: 05/17/2023]
Abstract
Boron neutron capture therapy (BNCT) is a promising cancer binary therapy modality that utilizes the nuclear capture reaction of thermal neutrons by boron-10 resulting in a localized release of high- and low-linear energy transfer (LET) radiation. Electrochemotherapy (ECT) is based on electroporation (EP) that induces opening of pores in cell membranes, allowing the entry of compounds. Because EP is applied locally to a tumor, the compound is incorporated preferentially by tumor cells. Based on the knowledge that the therapeutic success of BNCT depends centrally on the boron content in tumor and normal tissues and that EP has proven to be an excellent facilitator of tumor biodistribution of an anti-tumor agent, the aim of this study was to evaluate if EP can optimize the delivery of boronated compounds. We performed biodistribution studies and qualitative microdistribution analyses of boron employing the boron compound sodium decahydrodecaborate (GB-10) + EP in the hamster cheek pouch oral cancer model. Syrian hamsters with chemically induced exophytic squamous cell carcinomas were used. A typical EP treatment was applied to each tumor, varying the moment of application with respect to the administration of GB-10 (early or late). The results of this study showed a significant increase in the absolute and relative tumor boron concentration and optimization of the qualitative microdistribution of boron by the use of early EP + GB-10 versus GB-10 without EP. This strategy could be a tool to improve the therapeutic efficacy of BNCT/GB-10 in vivo.
Collapse
Affiliation(s)
- Marcela A Garabalino
- Departamento de Radiobiología, Comisión Nacional de Energía Atómica, Centro Atómico Constituyentes, Avenida General Paz 1499, B1650KNA, San Martin, Provincia Buenos Aires, Argentina.
| | - Nahuel Olaiz
- Departamento de Sistemas complejos, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Ciudad Universitaria, Pabellón II, C1428EHA, Ciudad Autónoma De Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, C1425FQB, Cuidad Autónoma De Buenos Aires, Argentina
| | - Agustina Portu
- Departamento de Radiobiología, Comisión Nacional de Energía Atómica, Centro Atómico Constituyentes, Avenida General Paz 1499, B1650KNA, San Martin, Provincia Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, C1425FQB, Cuidad Autónoma De Buenos Aires, Argentina
| | - Gisela Saint Martin
- Departamento de Radiobiología, Comisión Nacional de Energía Atómica, Centro Atómico Constituyentes, Avenida General Paz 1499, B1650KNA, San Martin, Provincia Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, C1425FQB, Cuidad Autónoma De Buenos Aires, Argentina
| | - Silvia I Thorp
- Sub-gerencia Instrumentación y Control, Centro Atómico Ezeiza, Camino Real Presbítero González y Aragón 15, B1802AYA, Ezeiza, Provincia Buenos Aires, Argentina
| | - Emiliano C C Pozzi
- Departamento de Reactores de Investigación y Producción, Centro Atómico Ezeiza, Camino Real Presbítero González y Aragón 15, B1802AYA, Ezeiza, Provincia Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, C1425FQB, Cuidad Autónoma De Buenos Aires, Argentina
| | - Paula Curotto
- Departamento de Reactores de Investigación y Producción, Centro Atómico Ezeiza, Camino Real Presbítero González y Aragón 15, B1802AYA, Ezeiza, Provincia Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, C1425FQB, Cuidad Autónoma De Buenos Aires, Argentina
| | - María E Itoiz
- Departamento de Anatomía Patología, Facultad de Odontología, Universidad de Buenos Aires, Marcelo T. de Alvear 2142, C1122AAH, Ciudad Autónoma De Buenos Aires, Argentina
| | - Andrea Monti Hughes
- Departamento de Radiobiología, Comisión Nacional de Energía Atómica, Centro Atómico Constituyentes, Avenida General Paz 1499, B1650KNA, San Martin, Provincia Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, C1425FQB, Cuidad Autónoma De Buenos Aires, Argentina
| | - Lucas L Colombo
- Instituto de Oncología Angel H. Roffo, Avenida San Martin 5481, C1417DTB, Ciudad Autónoma De Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, C1425FQB, Cuidad Autónoma De Buenos Aires, Argentina
| | - David W Nigg
- Idaho National Laboratory, 2525 Fremont Ave, Idaho Falls, ID, 83402, USA
| | - Verónica A Trivillin
- Departamento de Radiobiología, Comisión Nacional de Energía Atómica, Centro Atómico Constituyentes, Avenida General Paz 1499, B1650KNA, San Martin, Provincia Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, C1425FQB, Cuidad Autónoma De Buenos Aires, Argentina
| | - Guillermo Marshall
- Departamento de Sistemas complejos, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Ciudad Universitaria, Pabellón II, C1428EHA, Ciudad Autónoma De Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, C1425FQB, Cuidad Autónoma De Buenos Aires, Argentina
| | - Amanda E Schwint
- Departamento de Radiobiología, Comisión Nacional de Energía Atómica, Centro Atómico Constituyentes, Avenida General Paz 1499, B1650KNA, San Martin, Provincia Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, C1425FQB, Cuidad Autónoma De Buenos Aires, Argentina
| |
Collapse
|
|
7
|
Trivillin VA, Pozzi ECC, Colombo LL, Thorp SI, Garabalino MA, Monti Hughes A, González SJ, Farías RO, Curotto P, Santa Cruz GA, Carando DG, Schwint AE. Abscopal effect of boron neutron capture therapy (BNCT): proof of principle in an experimental model of colon cancer. RADIATION AND ENVIRONMENTAL BIOPHYSICS 2017; 56:365-375. [PMID: 28791476 DOI: 10.1007/s00411-017-0704-7] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/29/2016] [Accepted: 07/29/2017] [Indexed: 06/07/2023]
Abstract
The aim of the present study was to evaluate, for the first time, the abscopal effect of boron neutron capture therapy (BNCT). Twenty-six BDIX rats were inoculated subcutaneously with 1 × 106 DHD/K12/TRb syngeneic colon cancer cells in the right hind flank. Three weeks post-inoculation, the right leg of 12 rats bearing the tumor nodule was treated with BPA-BNCT (BPA-Boronophenylalanine) at the RA-3 nuclear reactor located in Buenos Aires, Argentina, at an absorbed dose of 7.5 Gy to skin as the dose-limiting tissue. The remaining group of 14 tumor-bearing rats were left untreated and used as control. Two weeks post-BNCT, 1 × 106 DHD/K12/TRb cells were injected subcutaneously in the contralateral left hind flank of each of the 26 BDIX rats. Tumor volume in both legs was measured weekly for 7 weeks to determine response to BNCT in the right leg and to assess a potential influence of BNCT in the right leg on tumor development in the left leg. Within the BNCT group, a statistically significant reduction was observed in contralateral left tumor volume in animals whose right leg tumor responded to BNCT (post-treatment/pre-treatment tumor volume <1) versus animals who failed to respond (post/pre ≥1), i.e., 13 ± 15 vs 271 ± 128 mm3. In addition, a statistically significant reduction in contralateral left leg tumor volume was observed in BNCT-responsive animals (post/pre <1) vs untreated animals, i.e., 13 ± 15 vs 254 ± 251 mm3. The present study performed in a simple animal model provides proof of principle that the positive response of a tumor to BNCT is capable of inducing an abscopal effect.
Collapse
Affiliation(s)
- Verónica A Trivillin
- Department of Radiobiology, Comisión Nacional de Energía Atómica (CNEA), Avenida General Paz 1499, B1650KNA San Martin, Provincia Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Ciudad Autónoma de Buenos Aires, Argentina
| | - Emiliano C C Pozzi
- Department of Research and Production Reactors, Centro Atómico Ezeiza, Comisión Nacional de Energía Atómica (CNEA), Provincia Buenos Aires, Argentina
| | - Lucas L Colombo
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Ciudad Autónoma de Buenos Aires, Argentina
- Instituto de Oncología Ángel H. Roffo, Ciudad Autónoma de Buenos Aires, Argentina
| | - Silvia I Thorp
- Department of Instrumentation and Control, Comisión Nacional de Energía Atómica (CNEA), Provincia Buenos Aires, Argentina
| | - Marcela A Garabalino
- Department of Radiobiology, Comisión Nacional de Energía Atómica (CNEA), Avenida General Paz 1499, B1650KNA San Martin, Provincia Buenos Aires, Argentina
| | - Andrea Monti Hughes
- Department of Radiobiology, Comisión Nacional de Energía Atómica (CNEA), Avenida General Paz 1499, B1650KNA San Martin, Provincia Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Ciudad Autónoma de Buenos Aires, Argentina
| | - Sara J González
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Ciudad Autónoma de Buenos Aires, Argentina
- Department of Instrumentation and Control, Comisión Nacional de Energía Atómica (CNEA), Provincia Buenos Aires, Argentina
| | - Rubén O Farías
- Department of Instrumentation and Control, Comisión Nacional de Energía Atómica (CNEA), Provincia Buenos Aires, Argentina
| | - Paula Curotto
- Department of Research and Production Reactors, Centro Atómico Ezeiza, Comisión Nacional de Energía Atómica (CNEA), Provincia Buenos Aires, Argentina
| | - Gustavo A Santa Cruz
- Department of Boron Neutron Capture Therapy, Comisión Nacional de Energía Atómica (CNEA), Provincia Buenos Aires, Argentina
| | - Daniel G Carando
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Ciudad Autónoma de Buenos Aires, Argentina
- Faculty of Exact and Natural Sciences, Universidad de Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina
| | - Amanda E Schwint
- Department of Radiobiology, Comisión Nacional de Energía Atómica (CNEA), Avenida General Paz 1499, B1650KNA San Martin, Provincia Buenos Aires, Argentina.
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Ciudad Autónoma de Buenos Aires, Argentina.
| |
Collapse
|
|
8
|
Pozzi ECC, Trivillin VA, Colombo LL, Monti Hughes A, Thorp SI, Cardoso JE, Garabalino MA, Molinari AJ, Heber EM, Curotto P, Miller M, Itoiz ME, Aromando RF, Nigg DW, Schwint AE. Boron neutron capture therapy (BNCT) for liver metastasis in an experimental model: dose–response at five-week follow-up based on retrospective dose assessment in individual rats. RADIATION AND ENVIRONMENTAL BIOPHYSICS 2013; 52:481-491. [PMID: 24077963 DOI: 10.1007/s00411-013-0490-9] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/26/2013] [Accepted: 08/24/2013] [Indexed: 06/02/2023]
Abstract
Boron neutron capture therapy (BNCT) was proposed for untreatable colorectal liver metastases. Employing an experimental model of liver metastases in rats, we recently demonstrated that BNCT mediated by boronophenylalanine (BPA-BNCT) at 13 Gy prescribed to tumor is therapeutically useful at 3-week follow-up. The aim of the present study was to evaluate dose–response at 5-week follow-up, based on retrospective dose assessment in individual rats. BDIX rats were inoculated with syngeneic colon cancer cells DHD/K12/TRb. Tumor-bearing animals were divided into three groups: BPA-BNCT (n = 19), Beam only (n = 8) and Sham (n = 7) (matched manipulation, no treatment). For each rat, neutron flux was measured in situ and boron content was measured in a pre-irradiation blood sample for retrospective individual dose assessment. For statistical analysis (ANOVA), individual data for the BPA-BNCT group were pooled according to absorbed tumor dose, BPA-BNCT I: 4.5–8.9 Gy and BPA-BNCT II: 9.2–16 Gy. At 5 weeks post-irradiation, the tumor surface area post-treatment/pre-treatment ratio was 12.2 ± 6.6 for Sham, 7.8 ± 4.1 for Beam only, 4.4 ± 5.6 for BPA-BNCT I and 0.45 ± 0.20 for BPA-BNCT II; tumor nodule weight was 750 ± 480 mg for Sham, 960 ± 620 mg for Beam only, 380 ± 720 mg for BPA-BNCT I and 7.3 ± 5.9 mg for BPA-BNCT II. The BPA-BNCT II group exhibited statistically significant tumor control with no contributory liver toxicity. Potential threshold doses for tumor response and significant tumor control were established at 6.1 and 9.2 Gy, respectively.
Collapse
|
|
9
|
Garabalino MA, Heber EM, Monti Hughes A, González SJ, Molinari AJ, Pozzi ECC, Nievas S, Itoiz ME, Aromando RF, Nigg DW, Bauer W, Trivillin VA, Schwint AE. Biodistribution of sodium borocaptate (BSH) for boron neutron capture therapy (BNCT) in an oral cancer model. RADIATION AND ENVIRONMENTAL BIOPHYSICS 2013; 52:351-361. [PMID: 23591915 DOI: 10.1007/s00411-013-0467-8] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/12/2012] [Accepted: 03/23/2013] [Indexed: 06/02/2023]
Abstract
Boron neutron capture therapy (BNCT) is based on selective accumulation of ¹⁰B carriers in tumor followed by neutron irradiation. We previously proved the therapeutic success of BNCT mediated by the boron compounds boronophenylalanine and sodium decahydrodecaborate (GB-10) in the hamster cheek pouch oral cancer model. Based on the clinical relevance of the boron carrier sodium borocaptate (BSH) and the knowledge that the most effective way to optimize BNCT is to improve tumor boron targeting, the specific aim of this study was to perform biodistribution studies of BSH in the hamster cheek pouch oral cancer model and evaluate the feasibility of BNCT mediated by BSH at nuclear reactor RA-3. The general aim of these studies is to contribute to the knowledge of BNCT radiobiology and optimize BNCT for head and neck cancer. Sodium borocaptate (50 mg ¹⁰B/kg) was administered to tumor-bearing hamsters. Groups of 3-5 animals were killed humanely at nine time-points, 3-12 h post-administration. Samples of blood, tumor, precancerous pouch tissue, normal pouch tissue and other clinically relevant normal tissues were processed for boron measurement by optic emission spectroscopy. Tumor boron concentration peaked to therapeutically useful boron concentration values of 24-35 ppm. The boron concentration ratio tumor/normal pouch tissue ranged from 1.1 to 1.8. Pharmacokinetic curves showed that the optimum interval between BSH administration and neutron irradiation was 7-11 h. It is concluded that BNCT mediated by BSH at nuclear reactor RA-3 would be feasible.
Collapse
Affiliation(s)
- Marcela A Garabalino
- Department of Radiobiology, National Atomic Energy Commission-CNEA, Avenida General Paz 1499, B1650KNA, San Martin, Buenos Aires, Argentina
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
|
10
|
Faião-Flores F, Coelho PRP, Arruda-Neto JDT, Camillo MAP, Maria-Engler SS, Rici REG, Sarkis JES, Maria DA. Boron uptake in normal melanocytes and melanoma cells and boron biodistribution study in mice bearing B16F10 melanoma for boron neutron capture therapy. RADIATION AND ENVIRONMENTAL BIOPHYSICS 2012; 51:319-329. [PMID: 22491822 DOI: 10.1007/s00411-012-0416-y] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/17/2011] [Accepted: 03/31/2012] [Indexed: 05/31/2023]
Abstract
Information on (10)B distribution in normal tissues is crucial to any further development of boron neutron capture therapy (BNCT). The goal of this study was to investigate the in vitro and in vivo boron biodistribution in B16F10 murine melanoma and normal tissues as a model for human melanoma treatment by a simple and rapid colorimetric method, which was validated by HR-ICP-MS. The B16F10 melanoma cell line showed higher melanin content than human melanocytes, demonstrating a greater potential for boronophenylalanine uptake. The melanocytes showed a moderate viability decrease in the first few minutes after BNCT application, stabilizing after 75 min, whereas the B16F10 melanoma showed the greatest intracellular boron concentration at 150 min after application, indicating a different boron uptake of melanoma cells compared to normal melanocytes. Moreover, at this time, the increase in boron uptake in melanoma cells was approximately 1.6 times higher than that in normal melanocytes. The (10)B concentration in the blood of mice bearing B16F10 melanoma increased until 90 min after BNCT application and then decreased after 120 min, and remained low until the 240th minute. On the other hand, the (10)B concentration in tumors was increased from 90 min and maximal at 150 min after application, thus confirming the in vitro results. Therefore, the present in vitro and in vivo study of (10)B uptake in normal and tumor cells revealed important data that could enable BNCT to be possibly used as a treatment for melanoma, a chemoresistant cancer associated with high mortality.
Collapse
Affiliation(s)
- Fernanda Faião-Flores
- Laboratory of Biochemistry and Biophysics, Butantan Institute, 1500 Vital Brasil Avenue, São Paulo, SP 05503-900, Brazil.
| | | | | | | | | | | | | | | |
Collapse
|
|
11
|
Heber EM, Kueffer PJ, Lee MW, Hawthorne MF, Garabalino MA, Molinari AJ, Nigg DW, Bauer W, Hughes AM, Pozzi ECC, Trivillin VA, Schwint AE. Boron delivery with liposomes for boron neutron capture therapy (BNCT): biodistribution studies in an experimental model of oral cancer demonstrating therapeutic potential. RADIATION AND ENVIRONMENTAL BIOPHYSICS 2012; 51:195-204. [PMID: 22271404 DOI: 10.1007/s00411-011-0399-0] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/05/2011] [Accepted: 12/27/2011] [Indexed: 05/31/2023]
Abstract
Boron neutron capture therapy (BNCT) combines selective accumulation of (10)B carriers in tumor tissue with subsequent neutron irradiation. We previously demonstrated the therapeutic efficacy of BNCT in the hamster cheek pouch oral cancer model. Optimization of BNCT depends largely on improving boron targeting to tumor cells. Seeking to maximize the potential of BNCT for the treatment for head and neck cancer, the aim of the present study was to perform boron biodistribution studies in the oral cancer model employing two different liposome formulations that were previously tested for a different pathology, i.e., in experimental mammary carcinoma in BALB/c mice: (1) MAC: liposomes incorporating K[nido-7-CH(3)(CH(2))(15)-7,8-C(2)B(9)H(11)] in the bilayer membrane and encapsulating a hypertonic buffer, administered intravenously at 6 mg B per kg body weight, and (2) MAC-TAC: liposomes incorporating K[nido-7-CH(3)(CH(2))(15)-7,8-C(2)B(9)H(11)] in the bilayer membrane and encapsulating a concentrated aqueous solution of the hydrophilic species Na(3) [ae-B(20)H(17)NH(3)], administered intravenously at 18 mg B per kg body weight. Samples of tumor, precancerous and normal pouch tissue, spleen, liver, kidney, and blood were taken at different times post-administration and processed to measure boron content by inductively coupled plasma mass spectrometry. No ostensible clinical toxic effects were observed with the selected formulations. Both MAC and MAC-TAC delivered boron selectively to tumor tissue. Absolute tumor values for MAC-TAC peaked to 66.6 ± 16.1 ppm at 48 h and to 43.9 ± 17.6 ppm at 54 h with very favorable ratios of tumor boron relative to precancerous and normal tissue, making these protocols particularly worthy of radiobiological assessment. Boron concentration values obtained would result in therapeutic BNCT doses in tumor without exceeding radiotolerance in precancerous/normal tissue at the thermal neutron facility at RA-3.
Collapse
Affiliation(s)
- Elisa M Heber
- Department of Radiobiology, National Atomic Energy Commission, San Martin, Buenos Aires, Argentina
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
|
12
|
Molinari AJ, Pozzi ECC, Hughes AM, Heber EM, Garabalino MA, Thorp SI, Miller M, Itoiz ME, Aromando RF, Nigg DW, Trivillin VA, Schwint AE. Tumor Blood Vessel “Normalization” Improves the Therapeutic Efficacy of Boron Neutron Capture Therapy (BNCT) in Experimental Oral Cancer. Radiat Res 2012; 177:59-68. [DOI: 10.1667/rr2729.1] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
|
13
|
Monti Hughes A, Pozzi ECC, Heber EM, Thorp S, Miller M, Itoiz ME, Aromando RF, Molinari AJ, Garabalino MA, Nigg DW, Trivillin VA, Schwint AE. Boron Neutron Capture Therapy (BNCT) in an oral precancer model: therapeutic benefits and potential toxicity of a double application of BNCT with a six-week interval. Oral Oncol 2011; 47:1017-22. [PMID: 21840244 DOI: 10.1016/j.oraloncology.2011.07.014] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2011] [Revised: 07/15/2011] [Accepted: 07/19/2011] [Indexed: 11/19/2022]
Abstract
Given the clinical relevance of locoregional recurrences in head and neck cancer, we developed a novel experimental model of premalignant tissue in the hamster cheek pouch for long-term studies and demonstrated the partial inhibitory effect of a single application of Boron Neutron Capture Therapy (BNCT) on tumor development from premalignant tissue. The aim of the present study was to evaluate the effect of a double application of BNCT with a 6 week interval in terms of inhibitory effect on tumor development, toxicity and DNA synthesis. We performed a double application, 6 weeks apart, of (1) BNCT mediated by boronophenylalanine (BPA-BNCT); (2) BNCT mediated by the combined application of decahydrodecaborate (GB-10) and BPA [(GB-10+BPA)-BNCT] or (3) beam-only, at RA-3 nuclear reactor and followed the animals for 8 months. The control group was cancerized and sham-irradiated. BPA-BNCT, (GB-10+BPA)-BNCT and beam-only induced a reduction in tumor development from premalignant tissue that persisted until 8, 3, and 2 months respectively. An early maximum inhibition of 100% was observed for all 3 protocols. No normal tissue radiotoxicity was detected. Reversible mucositis was observed in premalignant tissue, peaking at 1 week and resolving by the third week after each irradiation. Mucositis after the second application was not exacerbated by the first application. DNA synthesis was significantly reduced in premalignant tissue 8 months post-BNCT. A double application of BPA-BNCT and (GB-10+BPA)-BNCT, 6 weeks apart, could be used therapeutically at no additional cost in terms of radiotoxicity in normal and dose-limiting tissues.
Collapse
|
|
14
|
Molinari AJ, Pozzi ECC, Hughes AM, Heber EM, Garabalino MA, Thorp SI, Miller M, Itoiz ME, Aromando RF, Nigg DW, Quintana J, Santa Cruz GA, Trivillin VA, Schwint AE. “Sequential” Boron Neutron Capture Therapy (BNCT): A Novel Approach to BNCT for the Treatment of Oral Cancer in the Hamster Cheek Pouch Model. Radiat Res 2011; 175:463-72. [DOI: 10.1667/rr2148.1] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
|
15
|
Garabalino MA, Monti Hughes A, Molinari AJ, Heber EM, Pozzi ECC, Cardoso JE, Colombo LL, Nievas S, Nigg DW, Aromando RF, Itoiz ME, Trivillin VA, Schwint AE. Boron neutron capture therapy (BNCT) for the treatment of liver metastases: biodistribution studies of boron compounds in an experimental model. RADIATION AND ENVIRONMENTAL BIOPHYSICS 2011; 50:199-207. [PMID: 21132507 DOI: 10.1007/s00411-010-0345-6] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/08/2010] [Accepted: 11/13/2010] [Indexed: 05/17/2023]
Abstract
We previously demonstrated the therapeutic efficacy of different boron neutron capture therapy (BNCT) protocols in an experimental model of oral cancer. BNCT is based on the selective accumulation of (10)B carriers in a tumor followed by neutron irradiation. Within the context of exploring the potential therapeutic efficacy of BNCT for the treatment of liver metastases, the aim of the present study was to perform boron biodistribution studies in an experimental model of liver metastases in rats. Different boron compounds and administration conditions were assayed to determine which administration protocols would potentially be therapeutically useful in in vivo BNCT studies at the RA-3 nuclear reactor. A total of 70 BDIX rats were inoculated in the liver with syngeneic colon cancer cells DHD/K12/TRb to induce the development of subcapsular tumor nodules. Fourteen days post-inoculation, the animals were used for biodistribution studies. We evaluated a total of 11 administration protocols for the boron compounds boronophenylalanine (BPA) and GB-10 (Na(2)(10)B(10)H(10)), alone or combined at different dose levels and employing different administration routes. Tumor, normal tissue, and blood samples were processed for boron measurement by atomic emission spectroscopy. Six protocols proved potentially useful for BNCT studies in terms of absolute boron concentration in tumor and preferential uptake of boron by tumor tissue. Boron concentration values in tumor and normal tissues in the liver metastases model show it would be feasible to reach therapeutic BNCT doses in tumor without exceeding radiotolerance in normal tissue at the thermal neutron facility at RA-3.
Collapse
Affiliation(s)
- Marcela A Garabalino
- Department of Radiobiology, National Atomic Energy Commission, Avenida General Paz 1499, B1650KNA, San Martin, Province Buenos Aires, Argentina
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|